In light of this rationale of synergism between these two classes of inhibitors, we plan to study the anti-tumor activity and the immune effects of the combination of atezolizumab, anti-PD-L1, and selumetinib, MEK-I, in preclinical and clinical derived models of NSCLC. Here, CD274 is linked to neoplasm.